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Abstract
Alpha-methylacyl-CoA racemase (AMACR) is an enzyme playing an important role in the beta-
oxidation of branched-chain fatty acids and fatty acid derivatives. High expression levels of AMACR
have been described in various cancers, including prostate cancer, colorectal cancer and kidney
cancer. Because of its cancer-specific and frequent expression, AMACR could be an attractive
target for cytotoxic T-lymphocyte (CTL)-based immunotherapy for cancer. In the present study,
we examined the induction of AMACR-specific CTLs from prostate cancer patients' peripheral
blood mononuclear cells (PBMCs) and determined HLA-A24-restricted CTL epitopes.
RT-PCR and immunohistochemical analysis revealed that AMACR was strongly expressed in
prostate cancer cell lines and tissues as compared with benign or normal prostate tissues. Four
AMACR-derived peptides carrying the HLA-A24-binding motif were synthesized from the amino
acid sequence of this protein and analyzed to determine their binding affinities to HLA-A24. By
stimulating patient's PBMCs with the peptides, specific CTLs were successfully induced in 6 of 11
patients. The peptide-specific CTLs exerted significant cytotoxic activity against AMACR-
expressing prostate cancer cells in the context of HLA-A24. Our study demonstrates that AMACR
could become a target antigen for prostate cancer immunotherapy, and that the AMACR-derived
peptides might be good peptide vaccine candidates for HLA-A24-positive AMACR-expressing
cancer patients.
Introduction
Cytotoxic T lymphocytes (CTLs) play a major role in the
anti-cancer immune response [1]. Thus far, large numbers
of tumor-associated antigens and their CTL epitopes have
been identified [2,3]. High-throughput gene expression
profiling using a cDNA microarray allows for systematic
interrogation of transcriptionally altered genes. By com-
paring the mRNA expression profiles of cancerous lesions
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with non-cancerous lesions, a number of candidate anti-
gens for tumor-specific immunotherapy have emerged.
CTL epitope peptides derived from tumor-specific anti-
gens like the MAGE gene family have been employed for
pioneering studies of immunotherapy in cases of
advanced melanoma patients [4,5].
Castration-resistant prostate cancer is an aggressive dis-
ease with limited treatment options. Hence, there is great
need for new therapeutic strategies to treat prostate can-
cer, and recent progress in understanding of tumor immu-
nology has raised expectations that antigen-specific
immunotherapy may become a new modality for cancer
therapy. Alpha-methylacyl coenzyme A racemase
(AMACR) was identified as one of the genes that were
highly expressed in prostate cancer tissues through gene
expression profiling using a DNA microarray and RT-PCR
[6-8]. AMACR is an enzyme that catalyzes the racemiza-
tion of alpha-methyl carboxylic coenzyme A thioesters in
mitochondria and peroxisomes [9,10]. AMACR is
expressed abundantly in prostate cancer tissues as well as
colorectal cancer and lung cancer tissues, whereas it is
barely detected in benign tissues and normal prostate epi-
thelial cells [6-8]. Immunohistochemical staining for
AMACR is currently used in the clinical setting to support
the histological diagnosis of prostate cancer. Because it
has characteristics of cancer-specific expression and fre-
quent expression in various cancers, AMACR is an attrac-
tive target for cancer immunotherapy. In the present
study, we examined the induction of AMACR-specific
CTLs from prostate cancer patients' peripheral blood
mononuclear cells (PBMCs) and determined HLA-A24-
restricted CTL epitopes. Our study demonstrates for the
first time HLA-A24-restricted AMACR-derived CTL
epitopes that might be suitable for peptide vaccines for
AMACR-expressing cancer patients.
Materials and methods
Tissue Samples and PBMC
Surgically resected tissue specimens and PBMCs were
obtained from HLA-A*2402-positive prostate cancer
patients who were treated at Sapporo Medical University
Hospital (Sapporo, Japan) after obtaining their informed
consent. The study was approved by the Institutional
Review Board for Clinical Research at our university. The
expression of HLA-A24 molecules on PBMCs of cancer
patients was determined by flow cytometry using an anti-
HLA-A24 monoclonal antibody (c7709A2.6, kindly pro-
vided by Dr. P. G. Coulie, Ludwig Institute for Cancer
Research, Brussels Branch).
Cell Lines and Culture
Prostate cancer cell lines (LNCaP, DU145, and PC-3) and
proerythroleukemia cell line K562 were cultured in RPMI
1640 (Sigma, St. Louis, MO) supplemented with 10%
fetal bovine serum (FBS) (Filtron, Brooklyn, Australia).
T2-A*2402 cells, which are transporters associated with
antigen processing (TAP)-deficient T2 cells transfected
with HLA-A*2402 complementary DNA (cDNA) were
cultured in RPMI 1640 supplemented with 10% fetal
bovine serum and 800 μg/mL G418 (Invitrogen Life Tech-
nologies Co., Carlsbad, CA). LNCaP and DU145 are HLA-
A*2402-negative prostate cancer cell lines. To generate
LNCaP and DU-145 sublines expressing HLA-A24, HLA-
A*2402 cDNA was transduced into the cells by electropo-
ration using a Gene Pulser (Bio-Rad, Richmond, CA) as
reported previously [11]. The expression of HLA-A24 mol-
ecules on the cell lines was determined by flow cytometry
using the anti-HLA-A24 monoclonal antibody. LNCaP-
A*2402 and DU145-A*2402, stable HLA-A*2402 trans-
fectants of LNCaP and DU145 cells, respectively, were
established and cultured in RPMI 1640 supplemented
with 10% FBS and 500 ng/ml puromycin (Sigma).
Reverse transcriptase-polymerase chain reaction (RT-
PCR)
Multiple Tissue cDNA Panels (BD Biosciences Clontech,
Palo Alto, CA) were used as a template of normal tissue
cDNA. Total RNA was extracted using an RNeasy kit (Qia-
gen, Hilden, Germany). A cDNA mixture was synthesized
from 1 μg of total RNA by reverse transcription (RT) using
Superscript II and oligo (dT) primer (Invitrogen Life Tech-
nologies) according to the manufacturer's protocol. PCR
amplification was done in 50 μL of PCR mixture contain-
ing 1 μL of the cDNA mixture, 1 μL of KOD Plus DNA
polymerase (TOYOBO, Osaka, Japan) and 15 pmol of
primers. For specific detection of AMACR, forward primer
5'-CGG GGT ACC ATG GCA CTG CAG GGC ATC TCG-3'
and reverse primer 5'-ATA AGA ATG CGG CCG CGA GAC
TAG CTT TTA CCT TAT TAC T-3' were employed. As an
internal control, β-actin expression was detected by using
forward primer 5'-ACT GGC TCG TGA TGG ACT C-3' and
reverse primer 5'-TCA GGC AGC TCG TAG CTC TT-3'. The
amplification protocol consisted of denaturation for 15
seconds at 98°C, annealing for 45 seconds at 58°C and
extension for 4 minutes at 72°C for a total of 30 cycles,
using a GeneAmp PCR system model 2400 (Perkin-Elmer,
Foster City, CA).
Immunohistochemical Staining of Tissue Sections
Immunohistochemical staining was done with formalin-
fixed paraffin-embedded tissue sections of surgically
resected prostate cancer specimens. Four- to 5-μm-thick
sections were deparaffinized in xylene and rehydrated in
graded alcohols. Antigen retrieval was done by boiling
sections for 20 minutes in a microwave oven in preheated
0.01 mol/L sodium citrate buffer (pH 6.0). Endogenous
peroxidase activity was blocked by 3% hydrogen peroxide
in ethanol for 10 minutes. After blocking with 1% non-fat
dry milk in phosphate-buffered saline (PBS) (pH 7.4), theJournal of Translational Medicine 2009, 7:103 http://www.translational-medicine.com/content/7/1/103
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sections were reacted with a rabbit polyclonal antibody to
AMACR (clone RP134, Diagnostic BioSystems Co., Pleas-
anton, CA, USA) at 25 μg/mL or preimmune sera for 1
hour, followed by incubation with biotinylated goat anti-
rabbit IgG (Nichirei, Tokyo, Japan) for 30 minutes. Subse-
quently, the sections were stained with streptavidin-biotin
complex (Nichirei), followed by incubation with 3,3-
diaminobenzidine and counterstaining with hematoxy-
lin. The same tissues were immunostained with an anti-
prostate-specific antigen (PSA) polyclonal antibody
(DAKO, Denmark).
Peptides and Cytokines
AMACR-derived peptides were synthesized from the
amino acid sequence of AMACR based on the HLA-A24-
binding motifs. AMACR-derived peptides were provided
by Dainippon Sumitomo Pharmaceutical Co. (Osaka,
Japan). Two peptides were used as control peptides,
Epstein-Barr virus (EBV) LMP2-derived peptide (TYG-
PVFMSL) and human immunodeficiency virus (HIV) env-
derived peptide (RYLRDQQLLGI), which have been
shown to become CTL epitopes in the context of HLA-
A*2402 previously [12,13], and ovalbumin-derived SL-8
peptide (OVA257-264, SIINFEKL) was used as a negative
control peptide. These peptides were synthesized and pur-
chased from Sigma Genosys (Ishikari, Japan). The pep-
tides were dissolved in DMSO at a concentration of 5 mg/
mL and stored at -80°C. Human recombinant interleukin
(IL)-2, IL-4 and granulocyte macrophage colony-stimulat-
ing factor (GM-CSF) were kind gifts from Takeda Pharma-
ceutical Co. (Osaka, Japan), Ono Pharmaceutical Co.
(Osaka, Japan) and Novartis Pharmaceutical (Basel, Swit-
zerland), respectively. Human recombinant IL-7 was pur-
chased from Invitrogen Life Technologies.
Peptide Binding Assay
Peptide binding affinity to the HLA-A24 molecule was
assessed by HLA-A24 stabilization assay as described pre-
viously [13], based on the findings that MHC class I mol-
ecules could be stabilized on the cell surface in the
presence of binding peptides. After incubation of T2-
A*2402 cells in culture medium at 26°C for 18 hours, the
cells (2 × 105) were washed with PBS and suspended with
1 mL of Opti-MEM (Life Technologies) with or without
100 μg of peptide, followed by incubation at 26°C for 3
hours and then at 37°C for 3 hours. After washing with
PBS, the cells were incubated with the anti-HLA-A24 mon-
oclonal antibody at 4°C for 30 minutes, followed by incu-
bation with fluorescein isothiocyanate (FITC)-conjugated
rabbit anti-mouse IgG at 4°C for 30 minutes. The cells
were then suspended with 1 mL of PBS containing 1% for-
maldehyde, and analyzed by FACScan (Becton Dickinson,
Mountain View, CA). Binding affinity was evaluated by
comparing mean fluorescence intensity (MFI) of HLA-
A24 expression in the presence of peptide pulsation to
MFI in the absence of the peptide.
Peptide-specific CTL Induction with Immature Dendritic 
Cells and Phytohemagglutinin Blasts
PBMCs were isolated from prostate cancer patients by
standard density gradient centrifugation on Lymphoprep
(Nycomed, Oslo, Norway). PBMCs were incubated in
AIM-V medium (Invitrogen Life Technologies, Inc.) sup-
plemented with 2-mercaptoethanol (50 μM) and HEPES
(10 mM) for 2 hours at 37°C in a culture flask to separate
adherent cells and non-adherent cells. Adherent cells were
then cultured in the presence of IL-4 (1000 units/ml) and
GM-CSF (1000 units/ml) in AIM-V medium for 7 days to
generate monocyte-derived dendritic cells (DCs). The
adherent cells containing DCs and phytohemagglutinin
(PHA)-stimulated blasts were used as antigen-presenting
cells (APCs). CD8-positive T lymphocytes were isolated
from non-adherent cells with the MACS separation system
(Milteny Biotech, Bergish Blabach, Germany) using an
anti-CD8 monoclonal antibody coupled with magnetic
microbeads according to the manufacturer's instructions.
To obtain PHA-stimulated blasts, CD8-negative non-
adherent PBMCs were cultured in AIM-V medium con-
taining 1 μg/ml PHA (WAKO Chemicals, Osaka, Japan)
and 100 units/ml of IL-2 for 3 days, followed by washing
and cultivation in the presence of IL-2 (100 units/ml) for
4 days.
CTLs were induced from PBMCs of cancer patients by
using autologous DC and PHA-blasts as APCs as described
previously [14,15]. Briefly, APCs were cultured in AIM-V
medium supplemented with 50 μmol/L peptide at room
temperature for 2 hours, followed by washing with AIM-V
once, then irradiated (100 Gy) and used for stimulation of
CTLs. The CTL induction procedure was initiated by stim-
ulating CD8+ cells with peptide-pulsed autologous DCs at
a 20:1 effector/APC ratio in AIM-V supplemented with
HEPES, 2-ME, and IL-7 (10 ng/mL) for 7 days at 37°C.
The following stimulation was done with peptide-pulsed
PHA-blasts at a 10:1 effector/APC ratio. On the day after
the 2nd stimulation, IL-2 was added to the culture at a
concentration of 10 units/mL. The same CTL stimulation
cycle with PHA-blasts was then done twice more over a
period of 2 weeks. One week after the 4th stimulation,
cytotoxic activity of the CTL was measured by 51Cr release
assay.
Cytotoxicity Assay
The cytotoxic activities of CTLs were measured by 51Cr-
release assay as described previously [16]. Target cells were
labeled with 100 μCi of 51Cr for 1 hour at 37°C and
washed with RPMI 1640 three times. Then 51Cr-labeled
target cells were incubated with or without peptide and
effector cells at various effector/target ratios at 37°C for 6Journal of Translational Medicine 2009, 7:103 http://www.translational-medicine.com/content/7/1/103
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hours in V-bottomed 96-well microtiter plates. Then
supernatants were collected and the radioactivity was
measured with a gamma-counter. The % specific lysis was
calculated as follows: % specific lysis = (test sample
release - spontaneous release) × 100/(maximum release -
spontaneous release). For peptide-pulsed target cells, T2-
A*2402 cells were incubated with 1 μg/ml peptide at
room temperature for 1 hour before the assay. Moreover,
we also examined cytotoxic activity against LNCaP,
LNCaP-A*2402, DU145 and DU145-A*2402 prostate
cancer cells, which express endogenous AMACR.
ELISPOT Assay
ELISPOT plates were coated sterilely overnight with an
IFN-γ capture antibody (Beckton Dickinson Biosciences)
at 4°C. The plates were then washed once and blocked
with AIM-V medium containing 10% human serum for 2
hr at room temperature. CD8-positive T cells separated
from patients' PBMCs (5 × 103 cells/well), which were
stimulated in vitro with peptides, were then added to each
well along with HLA-A24-transfected CIR cells (CIR-A24)
(5 × 104 cells/well), which had been preincubated with
the AMACR peptide (10 μg/ml) or HIV peptide as a nega-
tive control. After incubation in a 5% CO2 humidified
chamber at 37°C for 24 hours, the wells were washed vig-
orously five times with PBS and incubated with a bioti-
nylated anti-human IFN-γ antibody and horseradish
peroxidase-conjugated avidin. Spots were visualized and
analyzed using KS ELISPOT (Carl Zeiss, Germany).
Statistical Analysis
We tested the statistical significance of cytotoxic activity of
CTLs induced with peptides using Student's t-test. A value
of p < 0.05 was considered to indicate statistical signifi-
cance.
Results
AMACR Expression in Normal Tissues, Prostate Cancer 
Cell Lines and Cancer Tissues
First the expression profile of AMACR in normal adult tis-
sues by RT-PCR was difined. We detected the overt expres-
sion of β-actin mRNA and AMACR mRNA in prostate
cancer line LNCaP, but only very weak expression of
AMACR mRNA was observed in normal adult liver and
pancreas (Figure 1A). In contrast, the AMACR mRNA level
was elevated in all three prostate cancer cell lines (LNCaP,
DU145 and PC-3) and in surgically resected prostate can-
cer tissues (Figure 1B and 1C). Low levels of expression
were detected in non-cancerous prostate tissues (Figure
1C).
Immunohistochemical analysis revealed that AMACR was
present in prostate cancer tissues in 27 (69.2%) of the 39
patients (Figures 2A and 2B). AMACR was weakly detected
in non-cancerous prostate tissues, but barely detected in
normal essential tissues such as adult liver and pancreas
by immunohistochemical staining. In contrast, PSA was
stained in both prostate cancer tissue and non-cancerous
tissue (Figure 2C). These data indicated that AMACR had
a mostly cancer-specific expression profile at both the
mRNA level and protein levels.
AMACR-derived Peptides Carrying HLA-A24 Binding Motif
Antigenic peptides derived from AMACR protein might be
presented by HLA class I molecules and recognized by
CD8-positive T cells. We focused on HLA-A*2402-
restricted peptides because of its high frequency in Asian
people. The amino acid sequence of AMACR protein was
screened for peptides that had an HLA-A24 binding motif,
such as 9- and 10-mer peptides with Y, F, M, or W at the
2nd position and L, I, F, or M at COOH-terminal position
[17]. Consequently, we found four peptides, AMACR1
(NYLALSGVL), AMACR2 (NMVEGTAYL), AMACR3
(FYELLIKGL) and AMACR4 (IYQLNSDKII) carrying the
HLA-A24 binding motif (Figure 3A). Next, we assessed
their binding affinities to HLA-A24 molecules by a bind-
ing assay using TAP-deficient T2 cells transfected with
HLA-A*2402. The MFI of cell surface HLA-A24 was clearly
increased in the presence of positive control peptides, EBV
peptide and HIV peptide, whereas it was not changed in
the presence of negative control peptide SL-8, indicating
the adequate qualification of this assay. The HLA-A24
level on the cell surface of T2-A*2402 cells was up-regu-
lated in the presence of AMACR1, AMACR2 and AMACR3
peptides, but not in the presence of AMACR4 peptide,
indicating that AMACR1, 2 and 3 peptides were possible
HLA-A24-presentable peptides (Figure 3B).
CTL Induction from PBMCs of HLA-A24-positive Prostate 
Cancer Patients
We attempted to induce AMACR peptide-specific CTLs
from PBMCs of HLA-A24 positive prostate cancer patients
and assessed their cytotoxic activity. PBMCs were cultured
with APCs pulsed with a mixture of three AMACR-derived
peptides. After stimulation four times with the peptides,
the cytotoxic activity against peptide-pulsed target cells
was examined by 51Cr-release assay. The CTLs induced by
the in vitro stimulation with AMACR peptides showed spe-
cific reactivity to the peptide-pulsed T2-A*2402 cells in 6
of 11 cases of HLA-A24-positive patients with AMACR-
positive prostate cancer (Table 1 and Figures 4, 5, 6 and
7). CTLs could not be induced in any of the patients with
AMACR-negative prostate cancer. In five cases (cases 1, 2,
3, 5 and 6) with AMACR-positive prostate cancer, CTLs
reacting to AMACR2 peptide-pulsed T2-A*2402 cells were
induced (Figure 5). With respect to AMACR1 and the 3
peptides, peptide-specific CTLs were induced in three
cases (cases 4, 5 and 6, Figure 4) and two cases (cases 5
and 6, Figure 6), respectively. Since the cytotoxic activity
of CTLs of case 6 was relatively low as compared with theJournal of Translational Medicine 2009, 7:103 http://www.translational-medicine.com/content/7/1/103
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other cases, peptide-specificity was assessed by ELISPOT
assay. CTLs of case 6 could release interferon-γ in response
to AMACR1, 2 and 3 peptides, but not in response to
AMACR4 peptide or HIV peptide (Figure 7), indicating
that the peptide specificity of the CTLs was consistent with
the cytotoxic assay.
Cytotoxic Activity of AMACR Peptide-specific CTLs 
Against HLA-A24-positive AMACR-positive Prostate 
Cancer Cell Lines
To confirm that CTLs induced with AMACR peptides
could exert cytotoxicity against AMACR-expressing pros-
tate cancer cell lines in an HLA-A*2402-restricted manner,
we examined their cytotoxic activity against prostate can-
cer cell lines that express endogenous AMACR by 51Cr-
release assay. LNCaP-A*2402 and DU145-A*2402, which
express both endogenous AMACR and gene-transfected
HLA-A*2402, were used as target cells. Parental LNCaP
and DU145 cells, HLA-A*2402-negative prostate cancer
cells, were used as negative control target cells. As shown
in Figure 8, CTLs induced from PBMCs of HLA-A*2402-
positive prostate cancer patients (cases 3, 4 and 5) with
AMACR peptides exerted cytotoxic activity against LNCaP-
A*2402 and DU145-A*2402 cells but not against LNCaP
and DU145 cells. These data implied that the peptide-spe-
cific CTLs were capable of recognizing endogenously
processed AMACR-derived peptides in an HLA-A24-
restricted manner.
Discussion
Specific immunotherapy for cancer is anticipated to
become an alternative or complementary therapy for
recurrent or metastatic disease. Successful immuno-
therapy depends on the identification of cancer-specific
Expression profiles of AMACR as assessed by RT-PCR Figure 1
Expression profiles of AMACR as assessed by RT-PCR. A. Expression of AMACR in normal tissues including heart, 
brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon and 
PBMC. LNCaP, a prostate cancer cell line was used as a positive control for AMACR expression. B. Expression of AMACR in 
prostate cancer cell lines. Beta-actin expression was detected as an internal control. AMACR mRNA was detected in three 
prostate cancer cell lines (LNCaP, DU145 and PC-3). C. Expression of AMACR in cancer tissues and noncancerous tissues 
from surgical specimens of two prostate cancer cases.Journal of Translational Medicine 2009, 7:103 http://www.translational-medicine.com/content/7/1/103
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antigens and the immunopotent CTL epitopes. Proteins
that are selectively expressed in cancer cells, but not in
normal adult tissues should become suitable targets for
cancer-specific immunotherapy. To establish effective
immunotherapy for prostate cancer, exploration of pros-
tate cancer-specific antigens has been conducted.
Although prostate-specific antigen (PSA) is a well-known
serum biomarker for prostate cancer, it has poor specifi-
city to cancer. PSA is highly expressed in noncancerous
prostatic tissues as well as in cancerous tissues [18-20] as
shown in Figure 2B in the present study. Indeed, serum
PSA levels are increased in patients with benign prostatic
diseases such as benign prostatic hypertrophy and prosta-
titis. Recently, new prostate cancer antigens have been
reported and examined as target antigens for cancer-spe-
cific immunotherapy [21-23]. In the present study, we
focused on AMACR, a novel antigen that is overexpressed
in a variety of tumor tissues, including prostate cancer.
AMACR was identified as a tissue biomarker for prostate
cancer by gene expression profiling of primary human
prostate cancer and benign prostatic hyperplasia (BPH)
using cDNA microarrays [8]. Initial studies reported that
AMACR was overexpressed in 94-100% of prostate can-
cers [6-8] though recent studies have demonstrated a
slightly lower expression rate in the range of 80-90% for
prostate cancer [24-26]. In our study, AMACR was
detected in about 70% of prostate cancer cases by immu-
nohistochemical analysis. This frequency was slightly
lower than those of previous reports. On the other hand,
its expression was very low in benign prostate glands,
which showed only focal and weak staining [6]. The func-
tion of AMACR in prostate cancer has not been clarified
yet. It has been reported that the function and expression
of AMACR might be independent of androgen receptor
signaling [27]. Recently, it has been reported that AMACR
is overexpressed in various tumor tissues, including renal
cell cancer, hepatic cancer, colon cancer and lung cancer.
Immunostaining of prostate cancer tissue with antibodies against AMACR and PSA Figure 2
Immunostaining of prostate cancer tissue with antibodies against AMACR and PSA. Surgically resected prostate 
cancer tissue was immunostained with an anti-AMACR antibody (panel A) or anti-PSA antibody (panel C). The lower column 
(panel B) is a magnified view of the box of panel A. A clear distinction is noted between cancerous tissue with strongly positive 
AMACR staining (long arrow) and noncancerous glands without AMACR staining (short arrow) whereas both of them are pos-
itive for PSA.Journal of Translational Medicine 2009, 7:103 http://www.translational-medicine.com/content/7/1/103
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Amino acid sequences of AMACR-derived peptides and their HLA-A24 binding assay Figure 3
Amino acid sequences of AMACR-derived peptides and their HLA-A24 binding assay. A. Amino acid sequences of 
AMACR protein and four peptides (AMACR1-4) with HLA-A24 binding motif (underlines). The predicted anchor residues to 
HLA-A24 are indicated in boldface within the amino acid sequences of the peptides. B Binding affinities of AMACR-derived 
peptides to HLA-A24 molecule were evaluated by the mean fluorescence intensity (MFI) of cell surface HLA-A24 molecules on 
T2-A*2402 cells that were pulsed with each peptide. EBV LMP2-derived peptide (TYGPVFMSL) and HIV env-derived peptide 
(RYLRDQQLLGI) were used as positive controls for HLA-A24-bound peptides. SL-8 peptide (SIINFEKL) was used as a nega-
tive control.
Table 1: Summary of clinicopathological characteristics and peptide-specific CTL induction from the peripheral blood mononuclear 
cells of prostate cancer patients
Case no. Age (years old) PSA (ng/ml) Gleason score Pathologic 
stage
AMACR 
expression
CTL induction Peptide 
specificity
1 60 6.7 4+3 T2aN0M0 + + AMACR2
2 73 6.0 3+3 T2aN0M0 + + AMACR2
3 65 11.6 4+3 T2bN0M0 + + AMACR2
4 64 15.6 3+4 T3aN0M0 + + AMACR1
5 67 18.4 4+5 T3aN0M0 + + AMACR1,2,3
6 67 14.4 4+3 T2bN0M0 + + AMACR1,2,3
77 1 1 0 . 9 3 + 5 T 3 b N 0 M 0 +- -
8 71 4.6 3+4 T2aN0M0 + - -
9 72 5.7 3+4 T2aN0M0 + - -
10 67 8.0 4+4 T2aN0M0 + - -
11 67 4.3 3+3 T2bN0M0 + - -
12 61 11.5 3+4 T2aN0M0 - - -
13 61 10.1 4+3 T2bN0M0 - - -
14 61 10.4 3+4 T2aN0M0 - - -
15 60 6.6 3+4 T2aN0M0 - - -Journal of Translational Medicine 2009, 7:103 http://www.translational-medicine.com/content/7/1/103
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AMACR1 peptide-specific CTL induction from PBMCs of HLA-A24-positive prostate cancer patients Figure 4
AMACR1 peptide-specific CTL induction from PBMCs of HLA-A24-positive prostate cancer patients. PBMCs of 
HLA-A24-positive prostate cancer patients (cases 4, 5 and 6) were stimulated four times with three kinds of AMACR peptide 
(AMACR1-3)-pulsed APCs and their cytotoxic activities were examined by 51Cr release assay at the indicated effector/target 
ratios. AMACR1 peptide-pulsed T2-A*2402 cells served as target cells. Non-pulsed T2-A*2402 cells were used as negative 
control target cells. K562 target cells were used for monitoring natural killer cell activity and lymphokine-activated nonspecific 
cytotoxicity.
AMACR2 peptide-specific CTL induction from PBMCs of HLA-A24-positive prostate cancer patients Figure 5
AMACR2 peptide-specific CTL induction from PBMCs of HLA-A24-positive prostate cancer patients. PBMCs of 
HLA-A24-positive prostate cancer patients (cases 1, 2, 3, 5 and 6) were stimulated four times with three kinds of AMACR pep-
tide (AMACR1-3)-pulsed APCs and their cytotoxic activities were examined by 51Cr release assay at the indicated effector/tar-
get ratios. AMACR2 peptide-pulsed T2-A*2402 cells served as target cells. Non-pulsed T2-A*2402 cells and K562 cells were 
used as negative control target cells.Journal of Translational Medicine 2009, 7:103 http://www.translational-medicine.com/content/7/1/103
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Because of the cancer specificity and high frequency of
AMACR expression, it can be an attractive target for cancer
immunotherapy. In this study, the immunogenic potency
of AMACR-derived peptides was assessed using PBMCs
from prostate cancer patients.
We focused on AMACR-derived peptides carrying the
HLA-A24 binding motif. The HLA-A*2402 genotype is
predominant in Japanese, accounting for about 60% of
the population [28]. Four AMACR-derived peptides
(AMACR1-4) carrying the HLA-A24-binding motif were
identified in the present study. By stimulating peripheral
blood lymphocytes of HLA-A24-positive/AMACR-
expressing prostate cancer patients with these AMACR-
derived peptides in vitro, peptide-specific CTLs were suc-
cessfully induced in 4 of 9 patients. Moreover, the CTLs
exerted significant cytotoxic activity against AMACR-
expressing prostate cancer cells in the context of HLA-A24,
indicating that AMACR-derived peptides might be useful
as prostate cancer vaccines for HLA-A24-positive/AMACR-
expressing prostate cancer patients. We demonstrated
HLA-A24-restricted CTL responses against AMACR-
derived peptides for the first time. Interestingly, the
immunogenic peptides were distinct among the patients.
However, it is likely that the AMACR2 peptide was the
most immunogenic of the three AMACR-derived peptides.
There may be some problems in introducing new CTL-
based immunotherapy for advanced recurrent and/or
metastatic prostate cancer patients. Even after four rounds
of in vitro stimulation of PBMCs with the peptides, cyto-
toxicity against AMACR-expressing tumor cells (% lysis)
was only around 20% at a 30:1 E:T ratio. Such weak cyto-
toxicity may be insufficient to induce a clinical anti-tumor
response. Since AMACR is involved in the bile acid syn-
thesis and there is weak expression in the liver, it is possi-
ble that T-cells with strong reactivity to AMACR might
have tolerance to the antigenic stimulation. Thus, further
studies are required to increase the cytotoxic potential of
the AMACR-specific CTLs. Moreover, it is reported that
AMACR expression is decreased in castration-resistant
metastatic diseases [29,30]. In addition, HLA class I
expression is decreased in almost 80% of prostate cancer
cases as reported by us and other groups [31-33]. The
down-regulation of HLA class I was observed more fre-
quently in metastatic sites than in the primary sites. Since
HLA class I has a critical role in the recognition of tumor
cells by CTLs, defects in antigen presentation could allow
the tumor cells to escape from killing by CTLs [34-36]. We
showed previously that HLA class I down-regulation was
caused at least in part by transcriptional silencing of the
β2-microglobulin gene by histone deacetylation in pros-
tate cancer cells, and HLA class I was restored by treatment
with histone deacetylase inhibitors [33]. It may be possi-
ble for CTL-based vaccines to be used in combination
with histone deacetylase inhibitors in immunotherapy for
prostate cancer.
Conclusion
In conclusion, we have provided evidence that AMACR is
a potent immunogenic antigen for prostate cancer and
AMACR3 peptide-specific CTL induction from PBMCs of  HLA-A24-positive prostate cancer patients Figure 6
AMACR3 peptide-specific CTL induction from 
PBMCs of HLA-A24-positive prostate cancer 
patients. PBMCs of HLA-A24-positive prostate cancer 
patients (cases 5 and 6) were stimulated four times with 
three kinds of AMACR peptide (AMACR1-3)-pulsed APCs 
and their cytotoxic activities were examined by 51Cr release 
assay at the indicated effector/target ratios. AMACR3 pep-
tide-pulsed T2-A*2402 cells served as target cells. Non-
pulsed T2-A*2402 cells and K562 cells were used as negative 
control target cells.
Peptide-specific interferon-γ release of CTLs Figure 7
Peptide-specific interferon-γ release of CTLs. PBMCs 
of HLA-A24-positive prostate cancer patient (case 6) were 
stimulated four times with four kinds of AMACR peptide 
(AMACR1-4)-pulsed APCs and peptide-specific interferon-γ 
release was analyzed by ELISPOT assay. CTLs could release 
interferon-γ in response to AMACR1, 2 and 3 peptides, but 
not in response to AMACR4 peptide or HIV peptide.Journal of Translational Medicine 2009, 7:103 http://www.translational-medicine.com/content/7/1/103
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AMACR-derived peptides might serve as a cancer vaccine
for HLA-A24-positive prostate cancer patients. It is possi-
ble that AMACR-targeting therapy might become a
rational modality in immunotherapy for various AMACR-
expressing cancers.
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